![]() |
|
|
Vol. 299, Issue 3, 1013-1020, December 2001
Department of Pharmacology and Toxicology, the University of
Kansas, Lawrence, Kansas (K.W.-S., M.T.K., R.S.); and Department of
Pharmacy, University of Regensburg, Regensburg, Germany (A.B.)
Fusion proteins allow for the analysis of receptor/G protein coupling
under defined conditions. The
2-adrenoceptor
(
2AR) fused to the long splice variant of
Gs
(Gs
L) exhibits a higher apparent
constitutive activity than the
2-adrenoceptor fused to
the short splice variant of Gs
(Gs
S).
Experimentally, this results in higher efficacy and potency of partial
agonists and in higher efficacy of inverse agonists at the
2AR fused to Gs
L relative to the
2AR fused to Gs
S, indicating that the
agonist-free
2AR and the
2AR occupied by
partial agonists promote GDP dissociation from Gs
L more
efficiently than from Gs
S. In fact, the GDP affinity of
Gs
S fused to the
2AR is higher than the
GDP affinity of Gs
L fused to the
2AR. We
asked the question whether the histamine H2-receptor
(H2R) exhibits similar coupling to Gs
splice
variants as the
2AR. To address this question, we
studied H2R-Gs
fusion proteins expressed in
Sf9 cells. In contrast to
2AR-Gs
fusion
proteins, the potencies and efficacies of partial agonists and the
efficacies of inverse agonists were similar at the H2R
fused to Gs
L and Gs
S as assessed by
guanosine-5'-O-(3-thio)triphosphate binding and/or
steady-state GTPase activity. However, the time course analysis of
guanosine-5'-O-(3-thio)triphosphate binding indicated
that Gs
S fused to the H2R possesses a higher
GDP-affinity than Gs
L fused to the H2R. Our
data show that the H2R fused to Gs
L and
Gs
S possesses similar constitutive activity and is
insensitive to differences in GDP affinity of Gs
splice variants. Thus, GDP affinity of G proteins does not generally determine
constitutive activity of receptors.
This article has been cited by other articles:
![]() |
A. I. Kaya, O. Ugur, S. S. Oner, M. Bastepe, and H. O. Onaran Coupling of {beta}2-Adrenoceptors to XL{alpha}s and G{alpha}s: A New Insight into Ligand-Induced G Protein Activation J. Pharmacol. Exp. Ther., April 1, 2009; 329(1): 350 - 359. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Weitl and R. Seifert Distinct Interactions of Human {beta}1- and {beta}2-Adrenoceptors with Isoproterenol, Epinephrine, Norepinephrine, and Dopamine J. Pharmacol. Exp. Ther., December 1, 2008; 327(3): 760 - 769. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-X. Xie, A. Kraus, P. Ghorai, Q.-Z. Ye, S. Elz, A. Buschauer, and R. Seifert N1-(3-Cyclohexylbutanoyl)-N2-[3-(1H-imidazol-4-yl)propyl]guanidine (UR-AK57), a Potent Partial Agonist for the Human Histamine H1- and H2-Receptors J. Pharmacol. Exp. Ther., June 1, 2006; 317(3): 1262 - 1268. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-X. Xie, P. Ghorai, Q.-Z. Ye, A. Buschauer, and R. Seifert Probing Ligand-Specific Histamine H1- and H2-Receptor Conformations with NG-Acylated Imidazolylpropylguanidines J. Pharmacol. Exp. Ther., April 1, 2006; 317(1): 139 - 146. [Abstract] [Full Text] [PDF] |
||||